Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib + chemotherapy induction followed by adebrelimab + apatinib + fluzoparib maintenance in platinum-resistant ovarian cancer
ChiCTR2500111250Phase 2Not yet recruiting
- Sponsor
- First Hospital of Nanping
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, Rivoceranib and fluzoparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by First Hospital of Nanping. Primary endpoint: Objective Response Rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranibfluzoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500111250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111250.